Patents by Inventor Junhong JEONG

Junhong JEONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody binding to TFPI and composition comprising the same
    Patent number: 10266607
    Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: April 23, 2019
    Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Dong-Sik Kim, Mi Jung Lee, Jae Chan Park, Sumin Lee, Heechun Kwak, SungHo Hwang, Hyung-Kwon Lim, Kisu Kim, Young Seoub Park, Junhong Jeong, Ki Joon Cho
  • NOVEL ANTIBODY BINDING TO TFPI AND COMPOSITION COMPRISING THE SAME
    Publication number: 20180030151
    Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
    Type: Application
    Filed: December 29, 2015
    Publication date: February 1, 2018
    Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Dong-Sik KIM, Mi Jung LEE, Jae Chan PARK, Sumin LEE, Heechun KWAK, SungHo HWANG, Hyung-Kwon LIM, Kisu KIM, Young Seoub PARK, Junhong JEONG, Ki Joon CHO